Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Go back to Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 71.04 +6.65 (10.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.39 | 52 Week High | $19.98 | |||
| Open | $65.03 | 52 Week Low | $10.52 | |||
| Day High | $71.20 | P/E | N/A | |||
| Day Low | $64.97 | EPS | $-1.45 | |||
| Volume | 1,120,778 | |||||
